Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...

Milestone Pharmaceuticals Inc.’s MIST share price has surged by 11.94%, which has investors questioning if this is right time ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...

TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, ...

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an ...